Titre
60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Kaufmann, M.
Auteure/Auteur
Puhan, M.A.
Auteure/Auteur
Salmen, A.
Auteure/Auteur
Kamm, C.P.
Auteure/Auteur
Manjaly, Z.M.
Auteure/Auteur
Calabrese, P.
Auteure/Auteur
Schippling, S.
Auteure/Auteur
Müller, S.
Auteure/Auteur
Kuhle, J.
Auteure/Auteur
Pot, C.
Auteure/Auteur
Gobbi, C.
Auteure/Auteur
Steinemann, N.
Auteure/Auteur
von Wyl, V.
Auteure/Auteur
Groupes de travail
Swiss Multiple Sclerosis Registry (SMSR)
Liens vers les personnes
Liens vers les unités
ISSN
1664-2295
Statut éditorial
Publié
Date de publication
2020
Volume
11
Première page
156
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Background: Multiple sclerosis (MS) is the most common chronic, non-traumatic, neurologic disease in young adults. While approximate values of the disease burden of MS are known, individual drivers are unknown. Objective: To estimate the age-, sex-, and disease severity-specific contributions to the disease burden of MS. Methods: We estimated the disease burden of MS using disability-adjusted life years (DALYs) following the Global Burden of Disease study (GBD) methodology. The data sources consisted of the Swiss MS Registry, a recent prevalence estimation, and the Swiss mortality registry. Results: The disease burden of MS in Switzerland in 2016 was 6,938 DALYs (95%-interval: 6,018-7,955), which corresponds to 97 DALYs per 100,000 adult inhabitants. Morbidity contributed 59% of the disease burden. While persons in an asymptomatic (EDSS-proxy 0) and mild (EDSS-proxy >0-3.5) disease stage represent 68.4% of the population, they make up 39.8% of the MS-specific morbidity. The remaining 60.2% of the MS-specific morbidity stems from the 31.6% of persons in a moderate (EDSS-proxy 4-6.5) or severe (EDSS-proxy ≥7) disease stage. Conclusions: Morbidity has a larger influence on the disease burden of MS than mortality and is shared in a ratio of 2:3 between persons in an asymptomatic/mild and moderate/severe disease stage in Switzerland. Interventions to reduce severity worsening in combination with tailored, symptomatic treatments are important future paths to lower the disease burden of MS.
PID Serval
serval:BIB_12570E9CE817
PMID
Open Access
Oui
Date de création
2020-04-01T17:25:22.366Z
Date de création dans IRIS
2025-05-20T19:31:15Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
32210908_BIB_12570E9CE817.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
430.11 KB
Format
Adobe PDF
PID Serval
serval:BIB_12570E9CE817.P001
URN
urn:nbn:ch:serval-BIB_12570E9CE8171
Somme de contrôle
(MD5):62eb7c6e1385cb8e4bedb6c674517e38